Home » Newsletters » BioWorld Science

BioWorld Science

March 22, 2006

View Archived Issues

Research Foundations of Orion and Farmos plan to merge

Laureate Pharma and Bradmer sign development and manufacturing agreement

p53 gene therapy feasible, active in esophageal carcinoma patients

Futility trial indicates creatine and minocycline deserve phase III investigation

Antihypertensives linked to reduced incidence of Alzheimer's disease

Antitumor and antiangiogenic validation of anti-S1P MAb from Lpath

Lilly and Biosite collaborate on biomarkers for Xigris therapy

Orphan drug designation for Zadaxin in malignant melanoma

Schering-Plough and PTC Therapeutics establish HCV collaboration

New phase II study for SNS-595 in small cell lung cancer

Medidur phase III trial recommended to continue

Preliminary 48-week from phase III psoriasis trial of ISA-247

Exelixis and Sankyo to develop novel therapies for cardiovascular disease

Phase II trial studying VRX-496 for HIV

NanoViricides achieves positive results in initial FluCide-I studies

POET-1 study of Altropane ended early for evaluation of data

NicOx and Merck to develop new antihypertensive drugs

Phase I/II study of obesity drug TM-30338 meets endpoints

Atorvastatin/glatiramer combination synergistic in multiple sclerosis model

LY-450139 investigated in Alzheimer's disease

RON: A novel target for anticancer therapy

OSI-930 reported safe in healthy volunteers

Thiovir active against H5N1 avian influenza chimeric virus strains

Elan completes sale of European Prialt rights to Eisai

Three new studies evaluate GEM OS1 in orthopedic indications

STRIDE study of I-vation Intravitreal Implant completes enrollment

Recent patents cover novel compounds for Alzheimer's and other neurological disorders

Therapeutic agents for gastrointestinal disorders disclosed in recent patent literature

Novel HIV vaccines jointly reported by Progenics and the Sloan-Kettering Institute

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...